Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
08/2005
08/31/2005CN1662250A Aqueous preparation containing oligopeptides and etherified cyclodextrin
08/31/2005CN1662244A Powdery respiratory tonic composition
08/31/2005CN1662243A Pharmaceutical composition
08/31/2005CN1662238A Peptide deformylase activated prodrugs
08/31/2005CN1662228A Compositions and method for transmucosal drug delivery and cryoprotection
08/31/2005CN1662227A Fluorosiloxane matrix controlled diffusion drug delivery systems
08/31/2005CN1662226A Monocompartment osmotic controlled drug delivery system
08/31/2005CN1662225A Popping oral pharmaceutical compositions
08/31/2005CN1662223A Spherical pellet containing a water-soluble active ingredient
08/31/2005CN1662222A Free-flowing, powdery composition containing alpha-liponic acid (-derivatives)
08/31/2005CN1662220A Breath freshening and oral cleansing product with cinnamaldehyde
08/31/2005CN1662177A Appts. and method for shape aesthetics
08/31/2005CN1662147A Delivery systems for functional ingredients
08/31/2005CN1662142A Oil body associated protein compositions, methods of and use thereof for reducing the risk of cardiovascular disease
08/31/2005CN1661044A DDS compound and method for measurement thereof
08/31/2005CN1661012A Miniaturized polypeptide of anti EB Virus tumour, application and preparation method
08/31/2005CN1660920A Polyethyleneglycol acid or active ester connected to omega amino acid at their ends, preparation method and application
08/31/2005CN1660444A Immunity coupler of containing monoclonal antibody Fab' segment of anti TV type collagenase poly glutamic acid-blemycin A5
08/31/2005CN1660443A Application of ramification of methoxypolythylene glycol, chemical modified general type red blood cell and preparation method
08/31/2005CN1660442A Transmission system for medicine containing trehalose and hyaluronic acid in use for curing burn and preparing method
08/31/2005CN1660441A Transmission system of drug for nasal cavity of containing trehalose and byaluronic acid, and preparation method
08/31/2005CN1660440A Triple combination of Planick-cholate phosphate in use for carrier of hard-soluble medication
08/31/2005CN1660439A Thinner for vaccine and preparation method
08/31/2005CN1660414A Stable preparation of interferon
08/31/2005CN1660412A Method of preparing microsphere of ethoxyl copolymer PLGA in interferon poly acid
08/31/2005CN1660074A Crystalline composition containing escitalopram
08/31/2005CN1660054A Rapidly disintegrating methylcellulose tablets
08/31/2005CN1216676C Chemical method for making pyrithione particle dispersions
08/31/2005CN1216643C Edible holographic products particularly pharmaceuticals and methods and apparatus for producing same
08/31/2005CN1216642C Anti-infective active substance combinations and use thereof for topical treatment of fungus diseases of toe and finger nails
08/31/2005CN1216636C Titanium slow-release composition
08/31/2005CN1216606C Stable aspirin ointment preparations
08/31/2005CN1216596C Acrylic enteric coating compsns.
08/31/2005CN1216595C Novel preparation for local use
08/31/2005CN1216594C Suspension comprising oxcarbazepine
08/30/2005US6936701 Glycoconjugates and methods
08/30/2005US6936661 Medical contact adhesive comprising a two phase adhesive matrix of polyacrylates and polyamine salts
08/30/2005US6936635 Composition for the treatment of respiratory disorders and a method for its use
08/30/2005US6936628 Orally administering one or more pharmaceutically acceptable acid neutralizing buffers with epothiolones (simultaneously, before or after) to increase the vioavailability of epothiolones
08/30/2005US6936597 A conjugate of blocked polymer with a biologically active compound containing reactive hydroxy or amino groups
08/30/2005US6936280 Method for preparing a composition by extraction of mother-of-pearl, composition obtained by said method and use thereof in cosmetics and dermatology
08/30/2005US6936276 For tissue regeneration, applying a multilayer biodegradable matrix of crosslinked proteins and/or polysaccharides, where each layer has porosity to accomodate living cells; bone, joint, cartilage repair
08/30/2005US6936268 Where the quantity of heat required for the evaporation of water is adjusted to a predetermined level, for a refreshing user feel; cosmetic applications for skin adjustment and beauty; contains a polyalkylene glycol, gelatin and/or polyacrylic acid
08/30/2005US6936265 Preparations of the w/o emulsion type with an increased water content based on low-viscosity, readily spreadable lipid components, additionally comprising one or more alkylmethicone copolyols and/or alkyldimethicone copolyols
08/30/2005US6936258 Staphylococcus antigen and vaccine
08/30/2005US6936255 adjuvant which is a preferential stimulator of TH1 cell response such as 3D-MPL and QS21
08/30/2005US6936253 Ganglioside-KLH conjugate vaccines plus QS-21
08/30/2005US6936250 Polysaccharide encapsualted antigen
08/30/2005US6936187 Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
08/30/2005CA2213774C Pharmaceutical compositions and devices for their administration
08/30/2005CA2103667C Liquid compositions based on 1,4 substituted piperidine derivatives
08/27/2005CA2491203A1 Topical antibacterial formulations
08/25/2005WO2005078084A1 Polyion complex carrying double stranded oligonucleic acid, process for producing the same and pharmaceutical composition containing the same
08/25/2005WO2005077424A2 Conjugate for destroying cancer cells
08/25/2005WO2005077423A2 Adept or gdept producing acetaldehyde
08/25/2005WO2005077422A2 Antibody linked cationic emulsions as drug delivery system
08/25/2005WO2005077421A1 A method of preparing polyethylene glycol modified interferon alpha 1b
08/25/2005WO2005077420A1 Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
08/25/2005WO2005077419A1 Soft capsule preparation
08/25/2005WO2005077407A1 Targeted atherosclerosis treatment
08/25/2005WO2005077402A1 Honey based gel formulations
08/25/2005WO2005077379A1 Remedy for external use for skin and mucosal injuries caused by viral infection
08/25/2005WO2005077376A1 A stable parental formulation of levomepromazine and a method for stabilizing said formulation
08/25/2005WO2005077374A1 Formulations of phosphodiesterase 5 inhibitors and methods of use
08/25/2005WO2005077370A1 Aqueous solution preparation containing camptothecins
08/25/2005WO2005077364A1 Transdermal solifenacin preparation and method of improving transdermal permeability thereof
08/25/2005WO2005077359A1 Stabilized pharmaceutical composition containing indoline compound
08/25/2005WO2005077357A1 Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
08/25/2005WO2005077346A1 Controlled release formulations
08/25/2005WO2005077338A1 Particles for inhalation rapid release properties
08/25/2005WO2005077333A2 Gel-based delivery of recombinant adeno-associated virus vectors
08/25/2005WO2005077090A2 Improved methods of producing antibody conjugates
08/25/2005WO2005077071A2 Therapeutic and diagnostic conjugates for use with multispecific antibodies
08/25/2005WO2005076975A2 Complexed polypeptide and adjuvant for improved vaccines
08/25/2005WO2005076829A2 Stable loratadine spill resistant formulation
08/25/2005WO2005076697A2 Cosmetic and pharmaceutical foam with solid matter
08/25/2005WO2005058967A8 Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
08/25/2005WO2005042590A3 Cyclodextrin amphiphilic derivatives, method for preparing same and uses thereof
08/25/2005WO2005034999A3 Composition comprising association complex of a pharmaceutical and a poloxamer
08/25/2005WO2004098513A3 Nasal administration of the lh-rh analog leuprolide
08/25/2005US20050187611 Drug coating with topcoat
08/25/2005US20050187212 Pharmaceutical composition for topical delivery of meloxicam
08/25/2005US20050187189 Artemisinins with improved stability and bioavailability for therapeutic drug development and application
08/25/2005US20050187188 Methods for the treatment of a traumatic central nervous system injury
08/25/2005US20050187186 useful for the treatment of cancer and other hyperproliferative disorders; a sphingolipid; lactic acid; and optionally a stabilizing agent; emulsion
08/25/2005US20050187174 RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
08/25/2005US20050187161 peptide sequences that selectively bind to fungal surface molecules; Biopanning and Rapid Analysis of Selective Interactive Ligands (BRASIL) provides for rapid and efficient separation of phage that bind to fungal surface molecules
08/25/2005US20050187160 soluble proteins containing free cysteine residues and having increased efficiency
08/25/2005US20050187157 Pharmaceutical compositions based on anticholinergics and pegsunercept
08/25/2005US20050187152 Prevention and treatment of hypergastrinemia
08/25/2005US20050187150 mimics the binding of heparin and heparan sulfate to the fibroblast growth factor (FGF) ligand and receptor; ternary complex of:an FGF ligand polypeptide; an FGF receptor polypeptide; and a heparin agonist or antagonist
08/25/2005US20050187147 Compositions and methods for increasing drug efficiency
08/25/2005US20050187143 Contains a surfactant and optionally a preservative, an isotonicizing agent, a buffer, and/or an excipient; has less than 04% by weight of zinc based on the insulin content of the formulation.
08/25/2005US20050187142 Contains a surfactant and optionally a preservative, an isotonicizing agent, a buffer, and/or an excipient; has less than 0.4% by weight of zinc based on the insulin content of the formulation.
08/25/2005US20050186660 Using calcitonin precursor protein as diagnostic tool in detection of cancer and sepsis
08/25/2005US20050186637 Hybridoma cell for use in propagation of immunoglobulins for treatment and prevention of autoimmune, pancreatic, blood and cell proliferative disorders
08/25/2005US20050186574 Anterior gradient 2 homolog (AGR2) for use as to in identifying modulator for treatment of asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, vision defects, inflammatory bowel and cell proliferative disorders
08/25/2005US20050186288 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
08/25/2005US20050186280 Carbopol" carboxy vinyl polymer stabilizer; topical formulations for eyes or skin; cream, ointment, gel, patches; drugs, cosmetics
08/25/2005US20050186268 Hard capsule
1 ... 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 ... 1712